ASPIrin in Reducing Events in Dialysis ( ASPIRED )
Sponsored by Guangdong Provincial People's Hospital
About this trial
Last updated 2 years ago
Study ID
GDPH-CH-2774
Status
Recruiting
Type
Interventional
Phase
Phase 4
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 5 years ago
What is this trial about?
People with kidney failure requiring dialysis have a much higher risk of developing
cardiovascular (CV) disease compared with the general population. A cardiac cause accounts
for 58% of all deaths in patients with end stage kidney disease (ESKD). At the same time,
this population has increased risks of clotting as well as bleeding episodes. While aspirin
is known to reduce cardiovascular complications in the general population, evidence to
support the use of aspirin in people with ESKD receiving dialysis therapy is currently
lacking. The ASPIrin to Reduce Event in Dialysis (ASPIRED) trial will test whether aspirin
use in dialysis patients safely improves outcomes compared with no aspirin use.
What are the participation requirements?
Inclusion Criteria
- Adult patients who are entered into the Chinese PD and HD dialysis registry
- Expected requirement for ongoing maintenance dialysis
- Willing and able to provide informed consent
Exclusion Criteria
- Requirement of antiplatelet agent or oral anticoagulation, in the view of the treating physician
- Contraindication to aspirin
- Dialysis requirement due to acute kidney injure I with the expectation of kidney function recovery
- History of haemorrhagic stroke or intracranial bleed within the past 12 months
- Coagulopathy from any cause